自敏化过渡金属配合物EPOs的制备及性质研究

单线态氧是分子氧的激发态，是光动力诊疗等领域中的重要活性分子。然而，由于单线态氧的高活性、寿命短的本征属性，使其容易与溶剂分子或者周围的其它物种反应，因此一般都需要原位产生单线态氧并应用。传统的光敏化方法产生单线态氧需要光敏剂在光照的条件下，激发周围环境中的分子氧，从而产生单线态氧。该方法需要同时存在光敏剂、光照以及分子氧环境，在光动力诊疗等实际应用中存在一定的局限性，如光照的可穿透性、分子氧的浓度等，并且癌细胞通常处于缺氧环境，氧浓度低，无法原位产生大量的活性单线态氧。具有自敏化性质的内过氧化物（EPOs）能够不依赖于外加光敏剂以及环境中的氧浓度，在一定的条件下能够可控地产生单线态活性氧，有可能发展成为新一代的光疗药物。本项目拟从分子水平出发，设计、合成系列自敏化过渡金属配合物EPOs，研究该类分子体系的基本理化性质，探索分子结构与性质的关系，发展一批温和条件下释放单线态氧的EPOs分子

Singlet oxygen is an excited state of molecular oxygen, which is an important active molecule in the field of photodynamic therapy. However, due to the intrinsic properties of its high activity and short lifetime, it is active to react with solvent molecules or other surrounding species, so it is necessary to generate singlet oxygen in situ for practical applications. The traditional photosensitization method to generate singlet oxygen requires the photosensitizer to sensitize molecular oxygen under irradiation. This method requires the simultaneous presence of photosensitizer, light, and molecular oxygen. There are several limitations in practical applications, such as the presence of external photosensitizers , light penetration, molecular oxygen concentration, etc. For instance, for photodynamic therapy, cancer cells are usually in an oxygen-deficient environment and the oxygen concentration in cancer cells is rather low. Hence, its only able to generate a limited amount of active singlet oxygen. Self-sensitized endoperoxides (EPOs) can produce singlet oxygen under external stimuli and are considered as the promising candidates for phototherapeutics, which is independent of the external photosensitizers and the molecular oxygen concentration for generating singlet oxygen. This project intends to design and synthesize a series of transition metal complexes-based self-sensitized EPOs, study the basic physical and chemical properties, explore the relationship between molecular structure and properties, and develop a series of transition metal complexes-based self-sensitized EPOs molecular materials.